Cited 16 times in
A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2022-09-02T01:16:40Z | - |
dc.date.available | 2022-09-02T01:16:40Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0002-8703 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190116 | - |
dc.description.abstract | The originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-making for dual antiplatelet therapy(1) duration after PCI. It is unknown if a simplified version of the score based on 4 factors (age, hemoglobin, creatinine clearance, prior bleeding), and lacking white-blood cell count, retains potential to guide DAPT duration. The 4-item PRECISE-DAPT was used to categorize 10,081 patients who were randomized to short (3-6 months) or long (12-24 months) DAPT regimen according to high (HBR defined by PRECISE-DAPT >= 25 points) or non-high bleeding risk (PRECISE-DAPT<25) status. Long treatment duration was associated with higher bleeding rates in HBR (ARD +2.22% [95% CI +0.53 to +3.90]) but not in non-HBR patients (ARD +0.25% [-0.14 to +0.64]; p(int) = 0.026), and associated with lower ischemic risks in non-HBR (ARD -1.44% [95% CI -2.56 to -0.31]), but not in HBR patients (ARD +1.16% [-1.91 to +4.22]; p(int) = 0.11). Only non-HBR patients experienced lower net clinical adverse events (NACE) with longer DAPT (p(int) = 0.043). A 4-item simplified version of the PRECISE-DAPT score retains the potential to categorize patients who benefit from prolonged DAPT without concomitant bleeding liability from those who do not. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Mosby | - |
dc.relation.isPartOf | AMERICAN HEART JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Age Factors | - |
dc.subject.MESH | Clinical Decision-Making* | - |
dc.subject.MESH | Dual Anti-Platelet Therapy / standards* | - |
dc.subject.MESH | Duration of Therapy* | - |
dc.subject.MESH | Hemorrhage / chemically induced | - |
dc.subject.MESH | Hemorrhage / epidemiology* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Percutaneous Coronary Intervention* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / adverse effects | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / therapeutic use* | - |
dc.subject.MESH | Postoperative Complications / chemically induced | - |
dc.subject.MESH | Postoperative Complications / epidemiology* | - |
dc.subject.MESH | Risk Assessment | - |
dc.title | A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Francesco Costa | - |
dc.contributor.googleauthor | David van Klaveren | - |
dc.contributor.googleauthor | Antonio Colombo | - |
dc.contributor.googleauthor | Fausto Feres | - |
dc.contributor.googleauthor | Lorenz Räber | - |
dc.contributor.googleauthor | Thomas Pilgrim | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.contributor.googleauthor | Stephan Windecker | - |
dc.contributor.googleauthor | Ewout W Steyerberg | - |
dc.contributor.googleauthor | Marco Valgimigli | - |
dc.identifier.doi | 10.1016/j.ahj.2020.01.014 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J00069 | - |
dc.identifier.eissn | 1097-6744 | - |
dc.identifier.pmid | 32151822 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0002870320300296 | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.citation.volume | 223 | - |
dc.citation.startPage | 44 | - |
dc.citation.endPage | 47 | - |
dc.identifier.bibliographicCitation | AMERICAN HEART JOURNAL, Vol.223 : 44-47, 2020-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.